Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Horizon Therapeutics names new president and CEO
Mr Walbert is currently president and CEO of IDM Pharma. Prior to IDM Pharma, Mr Walbert served as executive vice president of commercial operations at NeoPharm. George Tidmarsh,
Mr Walbert is currently president and CEO of IDM Pharma. Prior to IDM Pharma, Mr Walbert served as executive vice president of commercial operations at NeoPharm. George Tidmarsh,
The composite primary efficacy endpoint of the trial was ‘complete cure’ defined as negative mycology and clear nail. EcoNail is the company’s patented, topically-applied lacquer which contains the
The Peak surgery system combines the Pulsar Generator, which supplies pulsed plasma radiofrequency energy, with the Peak PlasmaBlade 4.0, a low-temperature surgical cutting and coagulation tool. This tissue
The round was led by new investor, Devon Park Bioventures, and included participation by Connecticut Innovations. Previous investors participating in the round included; Ascent Biomedical Ventures, Mitsubishi International
The approval of Apidra for pediatric use provides children with the option of using Apidra as part of their overall diabetes treatment plan, usually in combination with basal
The approved clinical trial will be open to patients with a variety of tumor types who have failed previous therapies. It will be conducted at a limited number
Proteros applied its industrial structural biology platform and proprietary technologies to deliver protein ligand structures to Almirall Scientists for a known, extremely challenging protein where little published data
The Risperdal Consta uses Alkermes’s proprietary Medisorb technology to deliver and maintain therapeutic medication levels in the body through just one injection every two weeks. Available in 12.5mg,
The financing was led by investments from two venture capital funds: Quaker BioVentures and SR One, the venture capital arm of GlaxoSmithKline. Previous investors, Safeguard Scientifics, Bay City
NuVasive is making a closing payment of $35 million in cash. Osiris will continue to supply Osteocel to NuVasive for a period of 18 months following the closing,